Piramal Pharma targets to double revenue in 5 years

Piramal Pharma aims to achieve $2 billion in annual revenue with a 25% operating margin by fiscal 2030, driven by its CDMO business. The company plans strategic investments to enhance capabilities in various segments and is also focusing on reducing debt. Currently, CDMO contributes significantly to its revenue.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FScmLoT
via IFTTT